Hypersensitivity to peanut or soya. Discontinue use if VTE or ATE is suspected or confirmed. Not for protection against HIV infections & other STDs. Circulatory disorders; VTE or ATE; symptoms of VTE/ATE eg, DVT, pulmonary embolism; CVA; MI. Risk factors for VTE eg, obesity (BMI >30 kg/m
2), prolonged immobilisation, major surgery, any legs or pelvis surgery, neurosurgery or major trauma, +ve family history, cancer, SLE, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis), sickle cell disease, increasing age. Risk factors for ATE eg, smoking, HTN, migraine, DM, hyperhomocysteinaemia, valvular heart disease, atrial fibrillation, dyslipoproteinaemia. Tumours; hypertriglyceridemia; jaundice &/or pruritus related to cholestasis; gallstones; porphyria; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss; hereditary angioedema; endogenous depression, epilepsy; GI disturbances. Irregular or w/drawal bleeding. History of chloasma gravidarum; avoid exposure to sun or UV radiation. Monitor serum K during therapy. Regularly measure BP & perform physical exam prior to therapy. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Ensure adequate alternative contraception w/ concomitant anticoagulant therapy eg, coumarins. Acute or chronic liver function disturbances; cholestatic jaundice &/or cholestasis-related pruritus; ALT elevations. Not to be used during pregnancy. Not recommended during lactation.
Sign Out
